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Abstract
Background: Resection of a gastrointestinal stromal tumor (GIST) of the rectum can be difficult because of the
particular location in the pelvis, and a large rectal GIST often requires abdominoperineal resection. Recent reports
demonstrate that neoadjuvant imatinib treatment improves surgical outcomes in patients with a rectal GIST, and
there are only a few reports of the effectiveness of laparoscopic surgery for a rectal GIST.
Case presentation: A 46-year-old man was found to have a rectal GIST that measured 80 mm and was located on
the anterior wall of the lower rectum. After 6 months treatment with imatinib, the tumor decreased in size to
37 mm, and laparoscopic low anterior resection was performed. The patient is currently alive without any evidence
of recurrence 37 months after surgery.
Conclusions: Neoadjuvant imatinib should be a treatment of choice for a large rectal GIST. When marked tumor
shrinkage is achieved, laparoscopic surgery may be the preferred procedure.
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Background
Gastrointestinal stromal tumors (GISTs) are rare tumors
with an estimated incidence of 1.5/100,000/year but are
the most common mesenchymal tumors of the gastro-
intestinal tract [1]. They are most commonly found in
the stomach (60 %) and small intestine (35 %), and <5 %
arise in the rectum [2]. Although complete surgical exci-
sion with histologically negative margins is the primary
treatment of choice for localized GISTs, resection of rec-
tal GISTs can be difficult in the narrow pelvic space, and
a large rectal GIST has a risk of rupture during surgery
and often requires abdominoperineal resection. GISTs
express KIT proto-oncogenic receptor tyrosine kinase
and commonly harbor activating mutations in the KIT
gene [3]. Imatinib is an inhibitor of tyrosine kinases in-
cluding KIT, and targets the aberrant signaling pathways
that are critical for tumor cell proliferation and survival,
thus showing anti-tumor activity [4]. The effectiveness
of imatinib in the treatment of GISTs was first described
in 2001 [5], and the remarkable response to imatinib in
unresectable or metastatic GISTs has led to the neoadju-
vant treatment strategy for locally advanced GISTs [6, 7].
Despite the excellent view of laparoscopy, there are only a
few that reported cases of its use in surgery for rectal
GIST [8, 9]. We report here a patient with a large rectal
GIST who safely underwent laparoscopic anus-preserving
surgery after neoadjuvant imatinib treatment.
Case presentation
A 46-year-old man was referred to our hospital because
of a 2-month history of anal pain and hematochezia. He
also complained of constipation, malaise, and body
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weight loss of 10 kg in 1.5 years. Computed tomography
(CT) and magnetic resonance imaging (MRI) demon-
strated a tumor measuring 80 mm in maximum diam-
eter on the anterior wall of the lower rectum and several
enlarged regional nodes (Fig. 1a). No distant metastases
were found. Colonoscopic examination revealed a large
submucosal tumor on the anterior wall of the rectum
just above the dentate line (Fig. 2). Core needle biopsy
of the tumor revealed bundles of spindle cells with posi-
tive immunohistochemical staining for c-kit antigen
(CD117) and CD34, but negative for other differentiation
markers such as desmin and S-100 protein (Fig. 3a, b).
The immunohistochemical findings led to the diagnosis
of a rectal GIST. Neoadjuvant imatinib treatment
(400 mg/day) was introduced, and soon after initiation,
anal pain was relieved. MRI after 1 month of treatment
showed marked shrinkage of the tumor to 52 mm, as
well as the lymph nodes. After treatment for 3 and
6 months, the tumor decreased to 44 and 37 mm, re-
spectively (Fig. 1b). CT examination revealed no distant
metastases. As a result of the dramatic tumor shrinkage
with neoadjuvant treatment and almost maximum
tumor response, we decided to operate at this point. The
adverse effect of imatinib was fatigue.
After 7 months treatment with imatinib, the patient
underwent laparoscopic low anterior resection with total
mesorectal excision, coloanal anastomosis, and diverting
ileostomy. Imatinib treatment was stopped 3 days before
surgery. Gross appearance of the specimen showed a
submucosal tumor measuring 43 × 35 mm, with a 10-
mm distal resection margin (Fig. 4a, b). Histological
examinations revealed that the tumor spread within
muscularis propria and protruded into submucosal layer
in its anal side, with negative resection margins, and
demonstrated an excellent response to imatinib with al-
most complete tumor necrosis (Fig. 4c). Metastasis was
not found in the 11 retrieved lymph nodes. Imatinib
treatment resumed on postoperative day 7, but was
interrupted 1 year later because of fatigue. The ileostomy
was reversed 3 months after the surgery, and the patient
is currently alive without any evidence of recurrence
37 months after surgery.
Discussion
We safely performed laparoscopic anus-preserving sur-
gery after neoadjuvant imatinib treatment for a large
rectal GIST. The primary treatment of choice for pa-
tients with localized GISTs is complete surgical excision
with negative microscopic margins [10, 11]. However, in
the restricted space of the pelvis, complete resection of a
large rectal GIST is difficult and often necessitates abdo-
minoperineal resection, with or without adjacent organ
resection. To reduce the size of the tumor, thereby low-
ering the risk of rupture during surgery, and increasing
the likelihood of anus preservation, we introduced neo-
adjuvant imatinib treatment in our patient. Many studies
Fig. 1 Sagittal view of pelvic MRI. a Before imatinib treatment, an 80-mm tumor was observed on the anterior wall of the lower rectum. b After
6 months treatment with imatinib, the tumor decreased to 37 mm
Fig. 2 Colonoscopic image before imatinib treatment. A large
submucosal tumor was observed on the anterior wall of the rectum
just above the dentate line
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have shown the effectiveness of imatinib in the treat-
ment of GISTs since the first report in 2001 [5].
Randomized clinical trials have reported response rates
of ~70 % in patients with unresectable or metastatic
GISTs [12, 13]. Another study demonstrated that, among
161 patients with locally advanced GISTs who received
neoadjuvant imatinib treatment, 129 patients (80.1 %)
had a partial response and only two (1.2 %) showed dis-
ease progression during treatment [14]. As for rectal
GISTs, several reports demonstrated that neoadjuvant
imatinib treatment improved R0 resection rates and de-
creased the risk of postoperative morbidity [6, 7]. There
seems to be no worldwide consensus, however, as to the
indications for neoadjuvant imatinib treatment, and it is
not recommended in the clinical practice guidelines for
GIST in Japan [15]. In contrast, in the National Compre-
hensive Cancer Network guidelines, it is recommended
that preoperative imatinib treatment should be consid-
ered if abdominoperineal resection is necessary to
achieve a negative resection margin, or if the surgeon
feels that multivisceral resection may be required [10].
In the European Society for Medical Oncology guide-
lines, neoadjuvant imatinib is recommended as a stand-
ard treatment if R0 surgery can be achieved through
function-sparing surgery in the case of cytoreduction,
and if the surgeon believes that the procedure is safer
after cytoreduction [11].
The clinical response to imatinib is reported to depend
on GIST genotype. Mutations in KIT exon 11 are the
most common type (65.8–73.1 %), followed by no muta-
tions (15.2–16.4 %) and mutations in KIT exon 9 (8.2–
8.4 %). Each of the other mutations comprises ~1 % of
the total. Mutations in KIT exon 11 correlated with bet-
ter response rates compared with no mutations and
Fig. 3 Core needle biopsy of the tumor. a Hematoxylin and eosin staining. b Immunohistochemical staining for c-kit antigen (CD117)
Fig. 4 Pathological examinations. a Gross appearance of the resected specimen. The tumor measured 43 × 35 mm in size, and a 10-mm distal
resection margin was secured. b Cross-sectional view of the tumor. Magnified view of the square area is shown in (c). c Histological examination
(hematoxylin and eosin staining). All of the tumor cells caused hyaline degeneration
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mutations in KIT exon 9, and the response rates were
69–71.7 %, 25–44.6 %, and 34–44.4 %, respectively [16, 17].
In patients with KIT exon 9 mutations, high-dose imatinib
(800 mg/day) resulted in improved response rates com-
pared with standard-dose therapy (400 mg/day) [17].
Hence, although mutational analysis is crucial to make a
clinical decision about neoadjuvant therapy, the patient re-
quired as rapid a start of imatinib treatment as possible,
without mutational analysis. This is partly because of the
anal pain and the wish to preserve the anus, and partly be-
cause of unavailability of the high-dose imatinib regimen in
Japan. Instead of the mutational analysis, we carried out
close monitoring of the tumor response by MRI, particu-
larly in the early phase of the treatment.
The appropriate timing of surgery is unknown. In ran-
domized clinical studies, the cumulative incidence of
response almost reached a plateau after treatment for 6–
8 months, and disease progression occurred in some
patients even in this period [12, 16]. Furthermore, it was
demonstrated that the median time to best response was
3.5 months, and little tumor shrinkage was obtained
after 9 months of treatment [18]. In the present case, al-
though dramatic tumor shrinkage was obtained after
1 month of treatment, only a little tumor shrinkage was
observed after 3 months. This represented almost max-
imum tumor response; therefore, we decided to operate at
this point. Surgery should be done promptly when tumors
become safely resectable, before disease progression.
Several approaches exist for resection of rectal GIST,
but the principle of surgery is complete resection with
an intact pseudo-capsule [10, 11]. Local resection, such
as transanal, trans-sacral, or transvaginal, may be suit-
able for small tumors, but for larger ones, radical resec-
tion, such as low anterior resection is preferable. Several
studies have demonstrated the association between local
resection and local recurrence [7, 19]. One study showed
that, among the 36 patients who underwent surgery for
rectal GIST, all five who developed local recurrence had
undergone local resection with positive margins, and
without perioperative imatinib treatment [7]. Radical re-
section was more likely to have resulted in negative re-
section margins (R0) than local resection (13 of 15 vs. 11
of 21, P = 0.03), although the radical resection group had
larger tumors. Another study also demonstrated that the
local recurrence rate after local resection was 77 % com-
pared with 31 % after radical resection, although the tu-
mors were smaller in local resection group [19].
The remarkable response to imatinib enabled us to
perform laparoscopic surgery safely. Several studies have
demonstrated that laparoscopic resection for a small- or
medium-sized gastric GIST is safe and effective when
performed by an expert surgeon [20]. However, there are
only a few reports of the effectiveness of laparoscopic
surgery for a rectal GIST; partly because of the rarity of
the disease [8, 9]. Although open radical resection for
rectal GIST resulted in lower rates of involved resection
margins and local recurrence than local resection, they
still showed high values [7, 19]. This is at least partly be-
cause of the poor visualization in the deep narrow pelvis.
Laparoscopy provides an excellent magnified view in the
deep confined space of the pelvis; therefore, laparoscopic
surgery should improve surgical outcomes and may be
the preferred procedure in patients with small- or
medium-sized rectal GISTs. Although we performed total
mesorectal excision to dissect the enlarged nodes detected
before the neoadjuvant treatment, the incidence of node
involvement has been reported as 5.0–8.8 % [21, 22], and
lymphadenectomy is usually not required [10, 11].
Conclusions
Neoadjuvant imatinib should be a treatment of choice
for large rectal GIST to increase the chance of anal pres-
ervation, and achieve surgical safety. When dramatic
tumor shrinkage is obtained, laparoscopic surgery may
be the preferred procedure.
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